Navigation Links
Anadys' Setrobuvir Named One of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch
Date:9/7/2011

SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that setrobuvir (ANA598), the Company's direct-acting antiviral (DAA) currently in Phase IIb development for hepatitis C, has been selected as one of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch.

"We are honored to have setrobuvir identified as a Top 10 infectious disease project," said Kevin Eastwood, Anadys' Senior Vice President of Corporate Development.  "This recognition reflects the scarcity of later-stage development assets in hepatitis C and the strong desire on the part of companies to assemble combination regimens to treat this disease.  With a readout next month of the 12-week data from an ongoing Phase IIb trial, Anadys has positioned setrobuvir as a well-characterized agent, ideally suited to complement other DAAs as the treatment of HCV evolves to a DAA combination treatment paradigm."

Setrobuvir was selected by independent experts at Windhover Information and Herndon Company.  The selection criteria included the breadth of business development opportunities, the current size and growth of the targeted market, and the strength of science underlying the program.  Many assets selected in this manner by Windhover in prior years have been the focus of subsequent attractive business transactions.

As a selected company, Anadys will present at Windhover's 6th Annual Therapeutic Area Partnerships conference November 30-December 2, 2011 in Boston, MA.  Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries.  

About setrobuvir in HCV

Setrobuvir, the Company's wholly-owned direct-acting antiviral or DAA, is an HCV RNA polymerase inhibitor that belongs to a chemical class referred to as non-nuc
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Announces Issuance of U.S. Patent Covering Setrobuvir (ANA598)
2. Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
3. Anadys Pharmaceuticals Appoints Barry Labinger to Its Board of Directors
4. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
5. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
6. Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference
7. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
8. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
9. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
10. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
11. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015   Regulus ... biopharmaceutical company leading the discovery and development of ... Kleanthis G. Xanthopoulos , Ph.D. has resigned as ... member of Regulus, Board of Directors, effective today, ...  Paul Grint, M.D., who previously served as Chief ...
(Date:6/1/2015)... The nuclear imaging market is estimated to grow to ... Nuclear medicine is the use of radioisotopes for the ... imaging used commonly are PET and SPECT. Till recently, ... applications like nuclear cardiology procedures. However, the trend is ... molybdenum-99 isotope which is in turn will lead to ...
(Date:6/1/2015)... DURHAM, N.C. , June 1, 2015  bioMérieux, ... vitro diagnostics, has been invited to join the ... of antibiotic use in the U.S. as a means ... various sectors, will gather tomorrow, June 2, 2015, to ... next five years to slow the emergence of antibiotic-resistant ...
Breaking Medicine Technology:Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 2Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 3Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 4North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 2North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 3bioMerieux Honored to Participate in the White House Forum on Antibiotic Stewardship 2bioMerieux Honored to Participate in the White House Forum on Antibiotic Stewardship 3
... Conference on Avian,Influenza at France's Pasteur Institute, PARIS, ... of,Novavax Inc.'s pandemic influenza vaccine provided protection,against a ... data presented here today at the Second International,Conference ... show that two 0.6 microgram doses of Novavax's,virus-like ...
... of Rare but Devastating,Condition , LONDON, June 1, ... of Leicester and have today (Friday June 1),announced ... rare but,devastating medical condition that can affect children ... clinicians and scientists from the two,universities have already ...
Cached Medicine Technology:Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 2Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 3Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 2World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 3World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 5
(Date:6/2/2015)... TheCelebrityDresses.com, a popular online store selling celebrity ... summer fashion cocktail dresses. The company carries more than ... be suitable for a wide variety of summer events ... and make high quality trendy special occasion dresses ... quality satin, chiffon and cotton. Their products feature a ...
(Date:6/2/2015)... 2015 Consumer Reports, the world’s ... announced its commitment to help wipe out antibiotic-resistant ... of antibiotics sicken about 2.25 million Americans each ... for Disease Control and Prevention. , The initiative ... Marta Tellado participating in the White House Forum ...
(Date:6/2/2015)... 2015 Amercanex, the American Cannabis ... to become Amercanex’s new Chief Technology Officer. Amercanex ... which cultivators, wholesale distributors and retail vendors can ... fully transparent intra-state market. , Jim Miller is ... technology space, helping innovative technology companies deliver on ...
(Date:6/2/2015)... Colleen’s Dream Foundation , with fundraising help from ... to support ovarian cancer research conducted by Cheng Wang, Ph.D. ... Colleen’s Dream Foundation Board of Directors. , Cundiff says the ... Colleen’s Dream Foundation and they couldn’t have picked a better ... a rising star in the ovarian cancer world,” says Cundiff. ...
(Date:6/2/2015)... 2015 Each year, Cosmetic Executive Women ... Awards. This year, the organization’s members – 8,000 industry ... the QVC® Beauty Quest Award at the 2015 Beauty ... (ME) Technology and 2-in-1 approach to skincare differentiated it ... brand’s loyal consumer and professional fan bases, QVC has ...
Breaking Medicine News(10 mins):Health News:Consumer Reports Aims to Stop the Spread of Superbugs 2Health News:Consumer Reports Aims to Stop the Spread of Superbugs 3Health News:Amercanex Names Jim Miller to CTO Position 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2
... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast:, ... conjunction with the 2009 ... corporate update will be presented by Stanley T. Crooke, M.D., ... Executive Officer of Isis., When: Tuesday, June 2, 2009, ...
... VIDEO ALERT: Additional audio and video resources, including excerpts ... the research, are available on the Mayo Clinic ... Mayo Clinic compared two popular television shows, CSI and ... clear differences between media portrayals of violent deaths versus ...
... Health Care CostsHARRISBURG, Pa., May 19 A budget ... or eliminate vital access to health care and services ... Everette James warned today."In today,s economic climate, access to ... Pennsylvanians. The Department of Health,s programs to expand access ...
... May 19 Boston Scientific Corporation (NYSE: BSX ... rating outlook to positive from stable, while affirming the Company,s ... reflects:, , ... its drug-eluting stent (DES) business and returning its cardiac rhythm ...
... Study Highlights the Clinical Success of Dental Implants ... 19 BioHorizons, a leader in the dental ... three-year prospective, controlled, multi-center study of implants with ... observed for Laser-Lok in vitro and ...
... in the womb , , TUESDAY, May 19 (HealthDay News) ... to become a regular smoker as a teen and ... University of Arizona researchers. , "Somehow smoke is changing ... Grad, an associate professor of clinical pediatrics at the ...
Cached Medicine News:Health News:Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in Conjunction with 2009 Annual Meeting of Stockholders 2Health News:CSI: Mayo Clinic Researchers Find Television Shows Inaccurately Portray Violent Crime 2Health News:Senate's Proposed Budget Threatens the Health of Millions of Pennsylvanians 2Health News:Fitch Raises Boston Scientific's Rating Outlook to Positive 2Health News:Fitch Raises Boston Scientific's Rating Outlook to Positive 3Health News:BioHorizons Reports on Comparative 3-Year Dental Implant Study Showing Significant Crestal Bone and Soft Tissue Retention Using Laser-Lok(R) Microchannels 2Health News:BioHorizons Reports on Comparative 3-Year Dental Implant Study Showing Significant Crestal Bone and Soft Tissue Retention Using Laser-Lok(R) Microchannels 3Health News:Kids More Apt to Smoke If Mom Did While Pregnant 2Health News:Kids More Apt to Smoke If Mom Did While Pregnant 3
... C spins up to 25,000 x g for quick ... and ease of use. The Model 5417 C is ... a cold room and can accommodate a variety of ... , Spin up to 16,400 rpm; 25,000 x ...
... laboratory floor model centrifuge meets UL and ... suitable for use in Class 1, Group ... gasoline, petroleum, naphtha, benzol, lacquer, solvent vapors ... is so strict that the EXD design ...
... Hybridization Oven/Shaker rigidly controls the temperature ... of hybridization and washing steps. This ... of nucleic acids and proteins immobilized ... with radioactive and nonradioactive labeling systems ...
... Oven with circular clear acrylic chamber for ... HybriCycler Oven features microprocessor operation for precise ... the unit., Carousel rotates at 11 ... ,easily removable , Bottle Capacity - ...
Medicine Products: